Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of dihydromyricetin in preparation of drugs for treating depression

A depression and drug technology, applied in the field of mental illness medicine and medicine, can solve the problem that the effect of mental illness has not been reported.

Inactive Publication Date: 2017-09-08
SUZHOU UNIV +1
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In recent years, pharmacological experiments have proved that dihydromyricetin has various effects such as analgesia, cough relief, broad-spectrum antibacterial, blood sugar lowering, blood lipid lowering, and anti-oxidation, but its effect on mental diseases has not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of dihydromyricetin in preparation of drugs for treating depression
  • Application of dihydromyricetin in preparation of drugs for treating depression
  • Application of dihydromyricetin in preparation of drugs for treating depression

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1 2

[0091] The effect of embodiment 1 dihydromyricetin (DHM) on acute depression

[0092] C57 mice aged 6-8 weeks and weighing 25±2g were randomly divided into five groups, including: normal saline group, dihydromyricetin 5mg / kg group, dihydromyricetin 10mg / kg group, dihydromyricetin 10mg / kg group, and dihydromyricetin 5mg / kg group. Myricetin 20mg / kg group (DHM dissolves with DMSO) and venlafaxine 10mg / kg group (venlafaxine is a kind of medicine for the treatment of depression already on the market, and its structural formula is ). Directly administer the drug continuously for three days, then do the tail suspension test and the forced swimming test, the results are as follows: figure 1 shown, where figure 1 A is the result of tail suspension experiment, figure 1 B is the result of the forced swimming experiment.

[0093] The results of administration for three days showed that: dihydromyricetin 10mg / kg, dihydromyricetin 20mg / kg and venlafaxine 10mg / kg groups had significant ...

Embodiment 2 2

[0094] Example 2 Effect of Dihydromyricetin on Chronic Unpredictable Mild Stimulation (CUMS)-Induced Depression

[0095]C57 mice that were 6-8 weeks old and weighed 25±2g were randomly divided into five groups, including: normal saline group, model group (CUMS is chronic unpredictable mild stimulation, and is a new type of constructed depression The method of the model, which mainly stimulates the mice in different ways, thereby simulating the process of the onset of human depression and some related symptoms after the onset, the models mentioned later are all CUMS modeling models), model + dihydromyricetin 10mg / kg group, model+dihydromyricetin 20mg / kg group and model+venlafaxine 10mg / kg group. First, the three groups of model + dihydromyricetin 10 mg / kg group, model + dihydromyricetin 20 mg / kg group and model + venlafaxine group were subjected to chronic unpredictable mild stimulation modeling, and the modeling process lasted for eight days. week, after the successful model...

Embodiment 3

[0097] Example 3 Changes in related proteins after chronic unpredictable mild stimulation model administration

[0098] The mouse whose behavior has been measured in Example 2 is decapitated and the brain is taken out, and the hippocampus in the brain is taken out, and then related proteins (such as p-CREB, t-ERK1 / 2, CREB, BDNF, GSK3β, pS9-GSK3β, p-ERK1 / 2, etc.) changes, the results are as follows image 3 shown.

[0099] The results showed that the therapeutic effect of dihydromyricetin on depression was realized by enhancing the phosphorylation of ERK1 / 2, GSK3β and CREB and increasing the content of BDNF in the brain.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of dihydromyricetin in preparation of a drug for treating depression, the drug comprising the dihydromyricetin can take effect rapidly after being applied, and accordingly, the depression is relieved and treated rapidly.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the technical field of mental disease medicine, in particular to the use of dihydromyricetin in the preparation of medicines for treating depression. Background technique [0002] Depressive symptoms are a clinical symptom of mood disorders. Depression is a type of mood disorder whose main clinical features are marked and persistent low mood, slow thinking, cognitive impairment, decreased volitional activity, and somatic symptoms. According to the latest WHO statistics, the global prevalence of depression and dysthymia is as high as 12.8%, and it is predicted that depression will become the second medical disease in the world by 2020. Depression not only damages the patient's health and reduces the quality of life, but also causes a great burden to the family and society. It has become a serious social and medical problem. Therefore, research on antidepressants has received wid...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61P25/24A23L33/10A23L2/52
CPCA23L2/52A23L33/10A23V2002/00A61K31/352A23V2200/322
Inventor 镇学初任兆翔颜鹏举钱勇谢天培
Owner SUZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com